Piper Sandler 說：在RFK Jr上任後，Moderna的股票下跌是一個“有吸引力的切入點”
Moderna’s (NASDAQ:MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good entry point for investors, according to Piper Sandler.
Piper Sandler, which reiterated Overweight rating on Moderna, says, “While COVID vaccinations continue to decline, mRESVIA disappoints and RFK Jr. introduces uncertainty, we see this as an attractive long-term entry point. Management reiterated product sales guidance of $3-3.5 billion in 2024, which we forecast will bottom at $2.9 billion in 2025 before returning to growth driven by new product launches.”
Vaccine makers in the U.S. felt the storm last week after the announcement, as analysts believe this could affect the perception of vaccines in the U.S., leading to reduced demand and sales.
The vaccine maker, which fell about 7% on Friday dropping to a 52-week low, swung back to profits on better-than-expected revenue in Q3 due to updated COVID-19 vaccine.
“Moderna could report interim Phase III CMVictory data on mRNA-1647 this year and has broad development plans for mRNA-4157+Keytruda with Merck. We reiterate our Overweight rating, however are cutting our target to $69 from $115.” Piper Sandler said in a statement.
Moderna has fallen about 63% so far this year. Currently, its trading up 1% premarket.
